Overview

Price chart · mood · technical indicators

RLMD

Relmada Therapeutics Incstock Healthcare

Biotechnology

$7.411974.47%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$0.32$7.94

Current: $7.41

Idea: EMA

1Y Return

+758.8%

Sharpe 3Y

1.00

Market Comparison

vs Healthcare Sector & Biotechnology Industry

RLMD

+1974.47%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-1.450.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$801.4MSmall cap

Wall Street coverage

$12.80median target· current $3.85 (+232.5%)5 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 9.26
P/S (TTM): 9001.90
EV/EBITDA: 0.54

Profitability & growth

ROE (TTM): -25.6%
Operating margin: 0.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: 0.83

Last earnings

Mar 24, 2026 · Estimate $-0.17 · Reported $-0.29

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Relmada Therapeutics Inc

Company profile

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the United States. The company is headquartered in New York, New York.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 2222 PONCE DE LEON BLVD., CORAL GABLES, FL
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$801.4M

Shares outstanding$104.9M

52W high$7.94

52W low$0.32

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

RLMD

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD)

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What Happened

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages

Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest

RLMD Stock Price, Quote & Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD)

[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3

Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics

RLMD SEC Filings - Relmada Therapeutics Inc 10-K, 10-Q, 8-K Forms

RLMD PE Ratio & Valuation, Is RLMD Overvalued

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement

With 20-plus years in drug development, Raj Pruthi joins PreveCeutical

Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know

Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know

RLMD stock surges 42% in a week: Here's what you should know

how Fair Value analysis spotted Relmada’s 65% gain in 2024

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest

Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock

About Relmada Therapeutics Inc

Classification

Company profile

RLMD

Market Comparison

RLMD Market Analysis

Overview

RLMD

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD)

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What Happened

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages

Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest

RLMD Stock Price, Quote & Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD)

[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3

Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics

RLMD SEC Filings - Relmada Therapeutics Inc 10-K, 10-Q, 8-K Forms

RLMD PE Ratio & Valuation, Is RLMD Overvalued

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement

With 20-plus years in drug development, Raj Pruthi joins PreveCeutical

Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know

Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know

RLMD stock surges 42% in a week: Here's what you should know

how Fair Value analysis spotted Relmada’s 65% gain in 2024

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest

Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock

About Relmada Therapeutics Inc

Classification

Company profile

RLMD

Market Comparison